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Abstract 
Aim: To asses liver markers in older patients with hip fracture (HF) in relation to age, comor-
bidities, metabolic characteristics and short-term outcomes.  
Methods: In 294 patients with HF (mean age 82.0±7.9 years, 72.1% women) serum alanine 
aminotransferase (ALT), gammaglutamyltransferase (GGT), alkaline phosphatase (ALP), albumin, 
bilirubin, 25(OH)vitaminD, PTH, calcium, phosphate, magnesium, adiponectin, leptin, resistin, 
thyroid function and cardiac troponin I were measured.  
Results: Elevated ALT, GGT, ALP or bilirubin levels on admission were observed in 1.7% - 9.9% of 
patients. With age GGT, ALT and leptin decrease, while PTH and adiponectin concentrations 
increase. Higher GGT (>30U/L, median level) was associated with coronary artery disease (CAD), 
diabetes mellitus (DM), and alcohol overuse; lower ALT (≤20U/L, median level) with dementia; 
total bilirubin >20μmol/L with CAD and alcohol overuse; and albumin >33g/L with CAD. Multi-
variate adjusted regression analyses revealed ALT, ALP, adiponectin, alcohol overuse and DM as 
independent and significant determinants of GGT (as continuous or categorical variable); GGT for 
each other liver marker; and PTH for adiponectin. The risk of prolonged hospital stay (>20 days) 
was about two times higher in patients with GGT>30U/L or adiponectin >17.14 ng/L (median 
level) and 4.7 times higher if both conditions coexisted. The risk of in-hospital death was 3 times 
higher if albumin was <33g/L.  
Conclusions: In older HF patients liver markers even within the normal range are associated with 
age-related disorders and outcomes. Adiponectin (but not 25(OH)vitaminD, PTH, leptin or re-
sistin) is an independent contributor to higher GGT. Serum GGT and albumin predict prolonged 
hospital stay and in-hospital death, respectively. A unifying hypothesis of the findings presented. 
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Introduction 
Global population ages rapidly, and by the year 
2050 the percentage of people >60 years of age is ex-
pected to reach 22%. Advanced age is the single major 
independent risk factor for most chronic diseases and 
functional deficits, accounting for 60% of all deaths 
worldwide. The liver because of its multitude meta-
bolic, homeostatic and detoxification functions plays a 
central role in aging and susceptibility to age-related 
diseases. Ageing is associated with significant loss of 
hepatic volume and blood flow, structural changes in 
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all liver cells, accumulation of ageing pigments at the 
cytoplasm and pseudocapillarization of the 
sinusoid.1-4 Over the past several years, substantial 
research has shown that alanine aminotransferase 
(ALT) and gamma-glutamyltransferase (GGT) activi-
ties decrease with old age.5-10 However, the relation-
ship between ageing and liver function and diseases 
remains obscure.11 For example, a number of reports 
concluded that in the elderly low ALT level is a strong 
and independent predictor of mortality,6, 8, 12-15 while 
in other studies of community-dwelling older adults14, 
16-18 and older twins,19 elevated serum ALT,16 aspar-
tate aminotransferase (AST), alkaline phosphatise 
(ALP)14, 17, 20 and, especially, GGT levels12, 14, 18, 20-29 
predicted all-cause, cardiovascular, and liver mortal-
ity.  
Numerous investigators found a positive asso-
ciation between ALT and/or GGT activities and 
metabolic syndrome, non-alcoholic fatty liver disease, 
type 2 diabetes mellitus (DM), cardiovascular disease 
(CVD), including coronary artery disease (CAD), hy-
pertension, heart failure and stroke, chronic kidney 
disease, and cancers,19, 27, 30-44 conditions which are 
highly prevalent in older individuals. The aforemen-
tioned associations were often evident across ALT 
and GGT activities values within the normal range,13, 
21, 23, 31, 45-47 independent of alcohol intake and other 
risk factors. Notably, although most of these studies 
did not focus specifically on the elderly population 
and the results have not been entirely consistent,48 
these associations were strong in young individuals, 
but weakened with age.21, 22, 24, 36, 42, 49, 50 
Liver is critically involved in metabolism of 
many factors contributing to bone health and hepatic 
osteodystrophy is a common well-documented com-
plication in patients with chronic liver disease.51-58 
Surprisingly, limited research has examined the liver 
function in older patients with hip fracture (HF).59, 60 
Liver markers, except low serum albumin concentra-
tion for mortality61-68 and increased postoperative 
complications,61, 69 are not currently included in the 
prognostic criteria.  
The potential pathogenic role of factors affecting 
both liver and bone, such as low vitamin D status, 
elevated PTH levels, dysregulation in secretion of 
adipokines (especially, adiponectin, leptin and resis-
tin), all of which are common in the elderly, virtually 
have not been investigated systematically in HF pa-
tients, despite growing evidence that the liver, the 
bone and adipose tissue are functionally interrelated 
organs.70 The aforementioned metabolic mechanisms 
are important for optimal function of many organs 
and tissues throughout the body and involved in 
numerous age-related comorbidities which may sub-
stantially contribute to poor outcomes in HF patients.  
To our knowledge, no published study has 
evaluated the relationship between liver function pa-
rameters and age, comorbidities, adipokines, vitamin 
D and PTH, as well as short-term outcomes in HF 
patients. 
The aim of this prospective observational study 
was three-fold: 1) to determine liver function param-
eters in older HF patients in relation to age, and 
whether markers of hepatic function are associated 
with comorbidities, 2) to evaluate the relationship 
between serum liver markers, on one hand, and se-
rum concentrations of vitamin D, PTH, adipokines 
adiponectin, leptin, and resistin, on the other, and 3) 
to assess the value of liver function markers on ad-
mission as predictors of short-term outcomes.  
Materials and Methods 
Patients 
The study population consisted of 294 patients 
(212 females and 82 males) aged 60 years and older 
with low-trauma osteoporotic HF admitted to The 
Canberra Hospital. Patients with high trauma, 
pathological HF, Paget’s disease, primary hy-
perparathyroidism or who did not have all serum 
variables of interest measured were not considered 
for the study. A detailed medical history, full physical 
examination and medication use were obtained along 
with demographic and anthropometric variables in all 
patients. 
Informed consent was obtained from all indi-
viduals or their carers. The study was approved by 
the regional ACT Health Human Research Ethical 
Committee and conducted according to the Helsinki 
Declaration (as revised in 2008). 
Laboratory Analyses  
After 12-hour overnight fast usually within 24 
hours after arrival at the Emergency Department ve-
nous blood samples were taken and sera were isolat-
ed. One serum sample was frozen and stored at -70°C 
until further analysis of adiponectin, leptin and resis-
tin. All other haematological and biochemical as-
sessments were performed at the day of collection. All 
patients had the following tests performed: liver 
function markers (ALT, GGT, ALP, albumin and total 
bilirubin), complete blood count, urea, creatinine and 
electrolytes, fasting blood glucose (and HbA1C in 
diabetic patients), thyroid function tests (TSH, T4 and 
T3 if indicated), 25 (OH) vitamin D [25(OH)D], intact 
PTH, total calcium, phosphate, magnesium, 
C-reactive protein (CRP) and cardiac troponin I 
(cTnI), adiponectin, leptin and resistin.  
Liver function tests were evaluated by using 
commercially available standard enzymatic reagents 
and diagnostic kits by spectrophotometry on the bio-
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chemical autoanalyzer Abbott Architect CI16200 
(Abbott Laboratories, IL 60064, USA). ALT, GGT and 
ALP were measured with enzymatic colorimetric 
methods, total bilirubin was analysed using diazo-
nium salt, total protein was tested by a Biuret method 
and albumin was measured using bromcresol green. 
The mean inter-assay and intra-assay coefficients of 
variations (CV) for these tests were within 1.1% – 
6.6%.  
 Serum levels of leptin were determined by en-
zyme-linked immunosorbent assay (ELISA) method 
(Diagnostic System Laboratories, Webster, TX, USA), 
total adiponectin and resistin by human ELISA kits 
(B-Bridge International, Mountain View, CA, USA). 
Intra- and interassay CV were less than 7% for these 
tests. All assays were performed according to the 
manufactures’ instructions with kits of the same lot 
number.  
Serum levels of 25(OH)D were determined by a 
radioimmunoassay kit (Dia Sorin, Stillwater, MN, 
USA; interassay CV 5.9–9.4%, intraassay CV<11.5%), 
intact PTH by solid-phase two-site chemiluminescent 
enzyme-linked immunometric assay on a DPC Im-
mulite 2000 analyzer (Diagnostic Products, Los An-
geles, CA, USA; interassay CV 6.2–7.0%, intraassay 
CV < 6%), cTnI by two-step chemiluminescent mi-
croparticle immunoassay (Chemiflex, Abbott Labs, 
Mississauga, Ontario, Canada; the minimum detecta-
ble limit 0.03 μg/L and the upper limit of reference 
range is 0.06 μg/L). Serum calcium concentration was 
corrected for serum albumin. Glomerular filtration 
rate (eGFR) was estimated using a standardized se-
rum creatinine-based formula normalized to a body 
surface area of 1.73 m² (Levey A 2010; Johnson D 
2012). All serum samples were processed in the same 
laboratory using the same methods and the same ref-
erence values. 
For liver enzymes 2 times the upper normal limit 
(UNL) cut-off levels were used to define abnormal 
tests. When aminotransferase activities were analysed 
as categorical variables median values were used: for 
ALT 20U/L and for GGT 30U/L, levels comparable 
with data in the literature (Ruhl C 2012; Wu W 2012).  
For the analyses, insufficiency of vitamin D was 
defined as 25(OH)D < 50 nmol/l and deficiency as 
25(OH)D < 25 nmol/l based on current recommenda-
tions. Secondary hyperparathyroidism (SHPT) was 
defined as elevated serum PTH (>6.8pmol/l, the up-
per limit of the laboratory reference range). 
Short-term outcomes included in-hospital 
all-cause mortality, prolonged length of stay (>20 
days), post-operative myocardial injury defined by 
cardiac troponin I rise (>0.06 μg/L), high inflamma-
tory response (CRP>100 mg/L) and being discharged 
to a permanent residential care facility. 
Statistical Analyses 
Statistical calculations were carried out using the 
Stata software version 10 (StataCorp, College Station, 
TX, USA). The summary statistics are presented as the 
mean ± standard deviation (SD) for continuous vari-
ables and as the number (percentages) for categorical 
variables. Comparisons between groups of patients 
were made by use Student’s t test for normally dis-
tributed continuous variables and a χ² test for cate-
gorical variables. The relationships between variables 
were examined by Pearson’s linear correlation test 
and multivariate logistic regression analyses after 
logarithmic transformation of continuous variables 
with a skewed distribution. When the dependent pa-
rameter was stratified by level to further assess the 
independent participation of each of the factors stud-
ied, odds ratios with 95% confidence intervals (CI) 
were measured in multivariate logistic regression 
models, incorporating into the models biomarkers as 
continuous variables and clinical characteristics (sex, 
presence of CVD, DM, excessive alcohol consump-
tion, history of smoking, etc) as categorical/ binary 
variables (yes, no). Bonferroni and Sidak adjustments 
for multiplicity were performed. To assess the signif-
icance of multicollinearity phenomena in multivariate 
regression analyses, the variance inflation factor was 
calculated. Results were considered statistically sig-
nificant if P values <0.05 (two-sided). 
Results 
Characteristics of patients 
Demographic, biochemical and haematological 
characteristics of the study population on admission 
are summarized in Table 1. The mean age of the pa-
tients was 82.0 years, 72.1% were women who were 
slightly older than men (+2.0 years, p=0.053), and 
89(30.2%) subjects were admitted from long care res-
idential facilities. There were 152 patients with a cer-
vical HF and 142 with an intertrochanteric HF. The 
prevalent comorbidities at the time of hospitalisation 
for HF included CVD (66.3%), chronic kidney disease 
(CKD)≥stage 3 (eGFR<60 ml/min/1.73m², 43.2%), 
dementia (27.8%), history of stroke or transient is-
chaemic attack (19.7%), type 2 DM (16.4%), chronic 
obstructive pulmonary disease (COPD, 11.0% ), and 
Parkinson’s disease (4.6%); 28(9.5%) patients con-
sumed alcohol 3 or more times a week. In the study 
population 51(17.3%) of patients had neither CVD, 
CKD, or DM, nor were alcohol overusers. The preva-
lence of abnormal liver tests was as follows: ALT 
(>2ULN, 80 U/L) in 5(1.7%) patients, GGT (>2ULN, 
128 U/L) in 23 (7.8%), ALP (>2ULN, 120 U/L) in 26 
(8.8%), bilirubin (>1ULN, 20µmol/L) in 29 (9.9%) and 
albumin (<33 g/L) in 64 (21.8%) subjects. The liver 
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function abnormalities were small in magnitude and 
not associated with clinically apparent hepatic dis-
ease. There were no gender differences in indicators 
of liver functions, haemoglobin, and glycosylated 
haemoglobin (HbA1c) values. However, women, 
compared to men, had higher PTH, leptin, adiponec-
tin and T4 concentrations and significantly lower 
mean 25(OH)D and eGFR levels.  
 
Table 1. General characteristics of patients with hip fractures by 
gender 
 Total Sample 
(n=294) 
Men 
(n=82) 
Women 
(n=212) 
P 
Value 
Age, years 82.0 ± 7.9 80.6 ± 8.3 82.6 ± 7.7 0.053 
Cervical/Trochanteric 
fracture, n 
152/142 38/44 114/98  0.298 
GGT, U/L 54.1 ± 95.6 57.9 ±106.0 52.6 ± 91.5 0.670  
ALT, U/L 23.0 ± 42.6 18.9 ± 11.1 24.6 ± 49.6 0.302 
ALP, U/L 105.4 ± 80.1 98.6 ± 64.6 108.2 ± 85.3 0.343 
Total bilirubin, µmol/L 12.4 ± 7.4 13.6 ± 7.1 11.9 ± 7.5 0.073 
Albumin, g/L 37.1 ± 6.3 37.4 ± 5.8 37.0 ± 6.5 0.573 
Haemoglobin, g/L 124.9 ± 17.1 127.8 ±16.8 123.7 ± 17.1 0.064 
Leptin, ng/ml 18.5 ± 23.2 11.7 ± 18.6 21.1 ± 24.3 0.002 
Adiponectin, ng/ml 17.5±7.4 15.6 ± 7.6 18.3 ± 7.1 0.007 
Resistin, ng/ml 18.7 ± 10.5 18.7 ± 10.7 18.6 ± 10.4 0.978 
Leptin/adiponectin ratio 1.5 ± 2.4 1.1 ± 1.6 1.6 ± 2.7 0.121 
Leptin/resistin ratio 1.4 ± 2.1 0.8 ± 1.0  1.6 ± 2.3 0.006 
Adiponectin/resistin ratio 1.3 ± 1.5 1.1 ± 0.9 1.4 ± 1.7 0.148 
25 (OH) D, nmol/L 37.3 ± 18.0 42.4 ± 18.2 35.3 ± 17.6 0.003 
PTH, pmol,L 6.9±5.6 5.5 ± 3.5 7.4 ± 6.1 0.009 
TSH (mU/L) 1.55 ±2.17 1.36 ± 1.35 1.62 ± 2.41 0.382 
Free T4 (pmol/L 15.9 ±3.54 15.2 ± 3.53 16.2 ± 3.50 0.021 
eGRF, ml/min/1.73m2 65.1 ± 23.7 71.2 ± 26.4 62.7 ± 22.2 0.006 
*HbA1c, % 6.6 ± 1.04 6.7 ± 1.29 6.6 ± 0.94 0.825 
Data are mean ± SD. GGT, gamma-glutamyltransferase; ALT, alanine aminotrans-
ferase; ALP, alkaline phosphatase; 25(OH) D, 25-hydroxyvitamin D; PTH, para-
thyroid hormone; TSH, thyroid-stimulating hormone; T4, thyroxin; eGFR, esti-
mated glomerular filtration rate; * HbA1c, glycosylated haemoglobin, measured 
only in patients with type 2 diabetes mellitus. 
 
Ageing mediated changes in serum metabolic 
parameters 
The results of Pearson’s correlations between 
liver markers, other parameters and age are shown in 
Table 2. GGT, ALT, leptin and eGFR were inversely 
associated with age, whereas adiponectin, resistin, 
PTH, creatinine, and urea were positively correlated 
with age. As might be expected, age showed a signif-
icant positive association with American Society of 
Anaesthesiologists (ASA) score (r=0.224; p=0.001) and 
presence of dementia (r=0.214; p=0.001). There was no 
significant association between any other studied pa-
rameters and age. 
Study subjects were further classified into three 
age groups: <75, 75 – 85 and >85 years (Table 3). In the 
oldest patients (aged > 85 years), compared to aged < 
75 years, the mean GGT activity was 50.6% and the 
ALT activity 48.4% lower; the mean leptin, 25(OH)D 
and eGFR levels were also 36.5%,14.6% and 29.4% 
lower, respectively, while adiponectin (+42.2%), re-
sistin (+25.1%) and PTH (+72.3%) demonstrated an 
opposite trend (all p for trend <0.05). No associations 
between age and ALP, albumin, bilirubin, TSH, T4, 
HbA1c were found. 
 
Table 2. Association between age and parameters of liver, renal, 
thyroid functions, adipokines and haemoglobin in older patients 
with hip fractures (Pearson correlation coefficients) 
Variable r P Value 
GGT - 0.198 0.001 
ALT -0.134 0.022 
ALP -0.076 0.192 
Bilirubin 0.006 0.920 
Albumin -0.060 0.308 
Leptin -0.159 0.007 
Adiponectin 0.248 <0.001 
Resistin 0.148 0.018 
Egfr -0.313 <0.001 
Creatinine 0.202 0.005 
Urea 0.296 0.001 
25 (OH)D -0.003 0.958 
PTH 0.250 <0.001 
TSH 0.032 0.594 
T4 -0.027 0.662 
Haemoglobin -0.110 0.058 
ASA score 0.224 0.001 
Dementia 0.212 0.001 
Data were log transferred before analysis (to achieve normal distribution). 
GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; TSH, 
thyroid-stimulating hormone; T4, thyroxin; eGFR, estimated glomerular filtration 
rate; ASA, American Society of Anaesthesiologists. 
 
Table 3. Liver and renal parameters, adipokines, vitamin D, PTH 
and haemoglobin levels in older patients with hip fracture by age 
 
Variable 
Age (years)  
P Value <75 (n=52) 75 – 85 
(n=145) 
>85 (n=97) 
Age, mean ± SD 69.3±5.0 81.2±2.7 90.1±3.5 <0.001 
GGT, U/L 85.6±65.1 50.7±77.2 42.3±61.5 0.010 
ALT, U/L 37.8±29.0 21.1±24.1 19.5±18.5 0.010 
ALP, U/L 114.6±89.5 104.1±76.1 102.5±66.4 0.564 
Bilirubin, µmol/L 12.3±8.3 12.5±7.7 12.2±6.4 0.948 
Albumin, g/L 38.1±5.4 36.8±6.1 36.9±6.1 0.438 
*HbA1c, % 6.6±1.0 6.6±1.0 6.5±1.2 0.971 
Leptin ng/ml 20.8±24.7 21.2±26.5 13.2±14.9 0.026 
Adiponectin, ng/ml 13.5±6.5 17.8±7.9 19.2±6.2 0.001 
Resistin, ng/ml 16.7±10.3 17.9±9.6 20.9±11.4 0.044 
25 (OH) D, nmol/L 39.7±15.9 37.1±19.0 33.9±17.5 0.035 
PTH, pmol/L 4.7±3.1 6.8±5.0 8.1±7.0 0.002 
eGFR, 
ml/min/1.73m² 
82.9±25.2 63.1±21.5 58.5±21.5 <0.001 
Hb, g/L 129.8±17.4 124.4±18.0 122.9±15.1 0.051 
Data are the mean ± SD. P value for trend. GGT, gamma-glutamyltransferease; ALT 
alanine aminotranferase; ALP, alkaline phosphatase; *HbA1c, glycosylated hae-
moglobin, measured only in patients with type 2 diabetes mellitus; 25(OH) D, 
25hydroxyvitamin D; PTH, parathyroid hormone; eGFR, estimated glomerular 
filtration rate; Hb, haemoglobin.  
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Links between liver markers and 
comorbidities 
Parameters of liver function were compared 
between patients with and without specific co-morbid 
conditions. Lower ALT levels (≤20IU/L) were associ-
ated with dementia (OR=2.11, 95%CI 1.10 – 4.05, p= 
0.015). Lower GGT levels (≤30U/L) were prevalent in 
females (OR=1.88, 95%CI 1.09 – 3.25, p= 0.016). Higher 
GGT levels (>30IU/L) were associated with coronary 
artery disease (CAD, OR=2.55, 95%CI 1.37 – 4.74, 
p=0.003), type 2 DM (OR=2.19, 95%CI 1.12 – 4.29, 
p=0.013), and excess alcohol consumption (>3 times a 
week, OR=6.39, 95%CI 1.6 – 29.57, p=0.002), while 
total bilirubin levels above 20µmol/L were associated 
with CAD (OR=2.56, 95% 1.01 – 6.42, p=0.025), cervi-
cal (vs. trochanteric) HF type (OR=3.26, 95%CI 1.27 – 
8.72, P=0.006) and alcohol overuse (OR=4.67, 95%CI 
1.12 – 18.19, p=0.008). Albumin concentrations above 
33g/L were associated with CAD (OR= 3.13, 05%CI 
1.21 – 8.5, p=0.009). On the other hand, the majority of 
51 patients without prevalent CVD, CKD≥3 stage, 
DM, and non-alcohol overusers, had ALT≤20U/L 
(70.6%), GGT≤30U/L (66.7%), albumin>33g/L 
(74.5%) and bilirubin<20µmol/L (94.1%). 
Correlations between liver markers and other 
parameters 
Pearson’s correlation coefficient between log 
ALT and log GGT was 0.372 (p<0.001). Both GGT and 
ALT were also significantly and positively associated 
with ALP (r= 0.426; p<0.001 and r= 0.141; p=0.015, 
respectively), and bilirubin (r=0.218; p=0.001, and 
r=0.171; p=0.003, respectively). ALT inversely corre-
lated with albumin (r= -0.124; p= 0.034). ALP was 
negatively associated with 25(OH)D (r= -0.187, 
p=0.002). Bilirubin correlated with resistin (r=0.151, 
p= 0.016), and PTH with adiponectin (r=0.193, 
p=0.002). No other associations were found between 
GGT, ALT, bilirubin, albumin, on one hand, and 
25(OH)D, PTH and adipokines, on the other hand. 
However, GGT correlated positively with TSH 
(r=0.116. p=0.05) and negatively with T4 (r= -0.185, p= 
0.002). There was also a significant inverse association 
between leptin and adiponectin (r= -0.178, p=0.005).  
Multiple linear regression analysis with GGT as 
the dependent variable and age, sex, ALT, ALP, bili-
rubin, albumin, eGFR, three adipokines (adiponectin, 
leptin and resistin), 25(OH)D, PTH, T4 levels, alcohol 
consumption (>3 times/week, yes/no), presence of 
DM (yes/no), and CVD (yes/no) as independent 
variables revealed eight independent and significant 
determinants of GGT (as a continuous variable): ALT, 
ALP, bilirubin, adiponectin, alcohol overuse, DM (all 
six positively related), albumin and age (both in-
versely related). This model explained 54.3% of the 
variance in serum GGT activity (Table 4). Similar 
analyses for four other liver markers, namely ALT, 
ALP, bilirubin and albumin, as dependent parameters 
in separate regression models showed that GGT was 
an independent and significant predictor for each of 
these liver function parameters (β=0.112, p=0.10; 
β=0.541, p<0.001; β=0.019, p=0.004; β=-0.012, p=0.039, 
respectively). When multiple linear regression analy-
sis was performed with adiponectin as the dependent 
variable three independent significant associations 
were found: age (β=0.232, p=0.001), male sex (β= 
-2.500, p=0.031) and PTH (β=0.185, p=0.0.40). 
 
Table 4. Multivariate linear regression analyses for serum gam-
ma-glutamyltransferase (GGT) level as a dependant continuous 
(model 1) and categorical (>30 U/L, model 2) variable  
 Model 1 Model 2 
 β P Value OR 95% CI P Value 
Age -2.464 <0.001 0.98 0.94-1.03 0.563 
Sex (m) 2.008 0.852 2.53 1.28-5.03 0.008 
ALT 0.263 0.010 1.04 1.01-1.06 0.013 
ALP 0.637 <0.001 1.01 1.01-1.02 0.015 
Bilirubin 1.869 0.004 1.01 0.94-1.06 0.602 
Albumin -1.554 0.039 1.01 0.95-1.06 0.738 
Adiponectin 1.403 0.034 1.06 1.02-1.11 0.009 
*Alcohol 92.368 <0.001 6.13 1.44-26.02 0.015 
DM 30.560 0.048 2.29 1.03-5.07 0.041 
  R²=0.5426 R²=0.1924  
β, parameter estimate/regression coefficient; OR, odds ratio; CI, confidence inter-
val; ALT alanine aminotranferase; ALP, alkaline phosphatase; DM, diabetes melli-
tus. *Alcohol consumption ≥3 times a week.  
Adjustments: age, sex, ALT, ALP, bilirubin, albumin, adiponectin, leptin, resistin, 
25(OH) D, PTH, estimated glomerular filtration rate (eGFR), alcohol overuse, 
presence of type 2 diabetes mellitus and cardiovascular disease. Only statistically 
significant associations (at least in one model) shown (p<0.05).  
 
 
In multivariate adjusted regression model that 
included GGT>30U/L as the dependent variable and 
the same independent variables, the significant asso-
ciations showed adiponectin, male sex, ALT, ALP, 
alcohol overuse and DM (Table 4, model 2). In multi-
variate regression analyses, ALT< 20U/L was inde-
pendently predicted only by GGT (OR=0.992, 
p=0.021), and albumin<33g/L was predicted only by 
GGT (OR=0.995, p=0.033) and ALP (OR=1.006, p= 
0.040). Compared to the rest of the cohort, the patients 
with GGT>30U/L (105.7 ± 65.5 vs.19.6 ± 5.1 U/L) had 
also significantly higher levels of ALT (31.9 ± 35.8 vs. 
17.2 ± 8.2U/L, p=0.004), ALP (129.4 ± 109.4 vs. 89.3 ± 
45.8U/L, p<0.001), bilirubin (13.7± 9.0 vs.11.5 ± 6.0 
µmol/L, p= 0.011), adiponectin (18.8± 7.4 vs. 16.6± 7.2 
ng/ml, p= 0.015) and resistin (20.3 ± 10.9 vs. 17.5 ± 
10.0 ng/ml, p=0.038). 
On subgroup analysis of patients with vitamin D 
insufficiency (25(OH)D<50 nmol/L, n=222), the sub-
jects with elevated PTH levels (>6.8 pmol/L, n=98) 
compared to those with PTH within the reference 
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range (n=124) demonstrated a significantly higher 
mean adiponectin concentration (19.8± 7.3 vs. 16.0±7.1 
ng/ml, p=0.001), while 25(OH)D levels were similar 
(29.0 ± 11.96 vs. 31.3 ± 11.83 nmol/L, p=0.194). It ap-
pears, therefore, that elevated PTH (not vitamin D 
insufficiency per se) modulates adiponectin produc-
tion by adipose tissue. 
Taken together, these data show strong bidirec-
tional associations between GGT and ALT, ALP, bili-
rubin (all positive) and albumin (negative), and con-
firm that both DM and alcohol overuse are inde-
pendent predictors of higher GGT. More importantly, 
the results indicate that in older patients with HF 
circulating adiponectin, which rises with ageing in 
parallel with PTH, is an independent and significant 
determinant of serum GGT activity. Multiple regres-
sion analysis adjusted for possible covariates, includ-
ing alcohol consumption and DM, identified that for 
every 1ng/ml increment of serum adiponectin con-
centration the probability of higher GGT(>30 U/L) 
increases by 6.2%. With age both GGT and ALT de-
crease, while PTH and adiponectin levels increase, 
and the latter seems to have a greater effect on serum 
GGT activity than age. These complex relationships 
are depicted in Figure 1. 
 
 
Figure 1. Relationships between age, liver function parameters, circulat-
ing levels of adiponectin and PTH (independent and significant associa-
tions shown). GGT, gamma-glutamyltransferase; ALT alanine aminotranferase; ALP, 
alkaline phosphatase; PTH, parathyroid hormone;  negative correlation. Ageing 
is associated with decreased GGT and ALT activities and higher serum PTH and 
adiponectin levels. PTH correlates with adiponectin and adiponectin is associated 
with higher GGT levels. A bidirectional relationship links GGT with ALT, ALP and 
bilirubin (positively) and albumin (negatively).  
 
Liver markers and short-term outcomes 
In our cohort, the prevalence of prolonged LOS 
(>20days) was 31.6% (n=94), and the in-hospital death 
rate was 4.8% (n=14). Myocardial injury (cTnI rise) 
was observed in 27.2% (n=80) of patients, a high 
post-operative inflammatory response (CRP>100 
mg/L) in 60.2% (n=177) and 49% of patients admitted 
from home have been discharged to a permanent 
residential care facility.  
When serum parameters (log transformed) of 
liver function were analysed as continuous variables 
by Pearson correlation, GGT activity correlated posi-
tively with prolonged hospital stay (r=0.140, p=0.020), 
and ALP correlated with a higher post-operative in-
flammatory response (r=0.123, p=0.036); albumin 
correlated inversely with in-hospital death (r= -0.137, 
p=0.005), postoperative cTnI rise (r=-0.292, p<0.001) 
and need to be discharged to a permanent residential 
care facility (r= -0.151. p=0.002). 
When each liver marker was examined as a cat-
egorical variable in multivariate adjusted analysis 
(with age, sex, other liver parameters and eGFR as 
independent variables), GGT >30U/L was associated 
with 1.9-fold increases in prolonged hospital stay and 
albumin<33g/L was associated with a 3-fold higher 
in-hospital mortality (Table 5). These findings re-
mained consistent or even stronger after further ad-
justment for serum leptin, adiponectin, resistin levels, 
ratios leptin/adiponectin, leptin/resistin and adi-
ponectin/resistin, 25(OH)D and PTH (model 2), as 
well as such potential confounders as alcohol con-
sumption, smoking (current or previous), presence of 
DM and CVD (Table 5, model 3). Of note, in multi-
variate analyses, adiponectin (p=0.031), PTH 
(p=0.001), age (p=0.051) and smoking history 
(p=0.007) were also independent predictors of pro-
longed hospital stay, while PTH (p=0.001) and male 
sex (p=0.03) were independently associated with 
in-hospital death. In patients with LOS>20 days, 
compared to the rest of the cohort, the mean adi-
ponectin levels were significantly higher (18.9±7.9 
vs.16.4± 7.0 ng/ml, p=0.022). Serum adiponectin 
concentration above the median level (17.14 ng/ml) 
2-fold increases the risk of prolonged hospital stay 
(OR 2.01, 95%CI 1.16-3.77, p=0.014) after adjustments 
for age, sex, liver markers, 25(OH)D, PTH, eGFR, 
presence of CVD and DM.  
Table 5. Liver function parameters at admission as independent 
predictors of poorer outcomes in older patients with hip fracture 
Parameter Outcome Model OR (95%CI) P Value 
GGT>30U/L LOS>20 days 1 1.86 (1.09 – 3.19) 0.023 
  2 1.98 (1.12 – 3.49) 0.019 
  3 1.74 (1.08 – 3.10) 0.038 
Albumin<33g/l In-hospital death 1 3.13 (1.01 – 9.09) 0.049 
  2 
3 
3.45 (1.08 – 11.11) 
11.11 (2.33 – 50.00) 
0.038 
0.003 
GGT, gamma-glutamyltransferase; LOS, length of hospital stay; OR, odds ratio; CI, 
confidence interval. 
Model 1: adjusted for age, sex, liver function parameters (GGT, ALT, ALP, biliru-
bin, albumin, except the evaluated categorical variable), and estimated glomerular 
filtration rate (n=293). 
Model 2: Model 1 plus serum leptin, adiponectin, resistin, ratios lep-
tin/adiponectin, leptin/resistin, adiponectin/resistin, 25(OH)D and PTH (n=285). 
Model 3: Model 2 plus alcohol consumption (≥3 times a week), smoking (current or 
previous), presence of type 2 diabetes mellitus, cardiovascular disease (hyperten-
sion, coronary artery disease, history of stroke, atrial fibrillation) (n=285). 
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The prognostic value of GGT>30U/L for pro-
longed LOS [accuracy 60.4%, 95%CI 54.7 – 66.1%, 
sensitivity 48.9%, 95%CI 39.9 – 57.8%; specificity 
65.8%, 95%CI 61.6 – 69.9%; PPV 39.8%, 95%CI 32.5 – 
47.1%; NPV 73.5%, 95%CI 68.9 – 78.1%] was compa-
rable with that of higher adiponectin level (cut-off 
17.14 ng/ml) [accuracy 57.9%, 95%CI 51.6 – 63.7%, 
sensitivity 61.5%, 95%CI 51.8 – 70.7%; specificity 
56.1%, 95%CI 51.5 – 60.4%; PPV 40.0%, 95%CI 33.6 – 
45.9%; NPV 75.4%, 95%CI 69.2 – 81.3%]. However, 
higher GGT and adiponectin levels show synergistic 
prognostic value for prolonged hospital stay: the risk 
increases 4.7-times in patients with both these char-
acteristics compared to subjects with none of such 
features (Figure 2). These two biomarkers, although 
interrelated, are associated with different specific 
pathogenetic processes; thus, for predicting LOS a 
two-marker approach (two biomarkers measured in 
parallel) is described. Compared with presence only 
of one of these biomarkers, combined GGT>30U/L 
plus adiponectin >17.14ng/ml, as would be expected, 
demonstrated an improvement of prognostic accuracy 
(72.3%, 95%CI 66.9 – 77.3), specificity (83.2%, 95% CI 
79.2 – 86.8%) and PPV (57.3%, 95%CI 47.4 – 66.6%), 
while the sensitivity (48.9%, 95%CI 40.4 – 56.8%), and 
NPV (77.8%, 95% CI 74.2 – 81.3%) unchanged.  
Serum albumin <33g/L has the following prog-
nostic value for in-hospital deaths: accuracy 77.2%, 
95%CI 75.0 – 79.8, sensitivity 42.9%, 95%CI 19.1– 
69.7%; specificity 78.9%, 95%CI 77.7 – 80.3%; PPV 
9.2%, 95%CI 4.1 – 15.0%; NPV 96.5%, 95%CI 95.1 – 
98.1%. 
 
 
Figure 2. Association between prolonged hospital stay (>20 days) and 
gamma-glutamyltransferase (GGT) and adiponectin profiles. Study patients 
were classified into four groups according to serum levels of GGT (≤30U/L or 
>30U/L) and adiponectin (≤17.14 ng/ml and >17.14 ng/ml). Values are odds ratio (OR) 
adjusted for age, sex, alcohol consumption, presence of type 2 diabetes and cardio-
vascular disease. Number of subjects in each group is shown in the column. Group 
1(n=101)-reference (OR=1.0), group 2(n=46)-high GGT and low adiponectin 
(OR=1.89, 95%CI 1.29 – 4.49, p=0.026), group 3 (n=72)- low GGT and high adi-
ponectin (OR= 1.94, 95%CI 1.64 -3.22, p=0.004), group 4 (n= 75)- high GGT and high 
adiponectin (OR=4.72, 95%CI 2.58 – 8.65, p=0.001). Of note, both higher serum 
GGT (>30U/L) and adiponectin (>17.14 ng/L) levels are synergistically associated with 
prolonged LOS. 
Discussion 
Main findings  
The results of this observational study of older 
HF patients showed that: (1) the prevalence of ab-
normal liver function tests is relatively low, but he-
patic functions (even within normal range) are asso-
ciated with common age-related disorders, (2) with 
age GGT and ALT activities decrease, while serum 
PTH and adiponectin concentrations increase, (3) ad-
iponectin is an independent contributor to higher 
GGT, which, in turn, demonstrates bidirectional links 
with ALT, ALP, bilirubin and albumin levels, and (4) 
GGT>30U/L and albumin<33g/L on admission, re-
gardless of other traditional risk factors, are useful 
independent predictors of prolonged LOS and 
in-hospital mortality, respectively.  
Our work corroborates previous studies show-
ing age-related decline in hepatic function, extends 
the understanding of the liver status and the role of 
adipokines, especially adiponectin, in its regulation in 
the elderly patients with HF, and presents novel 
findings of pathophysiological and clinical im-
portance. 
Liver markers and related parameters in 
patients with hip fracture according to age 
We found that in older HF patients the preva-
lence of abnormally elevated ALT, GGT, ALP or bili-
rubin on admission was relatively low (<10%, ranging 
between 1.7% and 9.9%) and comparable with or even 
lower than that reported in population-based 
studies,17, 71-75 as well as in a cohort of orthopaedic 
patients.59 
In our study, ageing was closely linked with de-
cline in GGT, ALT and leptin concentrations and in-
creasing adiponectin and PTH levels, both in correla-
tion analyses and when young old (<75 years) pa-
tients where compared to the old-old (>85 years); ad-
iponectin, leptin and PTH concentrations were sig-
nificantly higher in females than in males. These 
findings are consistent with many, but not all 21, 76, 77 
previous reports that serum GGT5, 9 and ALT6, 8-10, 73, 
78-81 activities (within reference range as well as ele-
vated) are negatively associated with age. We observe 
neither a decline in serum albumin, nor an increase in 
bilirubin with increasing age as it was reported by 
some authors.9 No gender dependence in the mean 
values of liver markers was found, although lower 
GGT levels (≤30U/L) were about 2-times prevalent in 
females; this is in agreement with previous studies 
that men had significantly higher concentrations of 
GGT than women.5, 21, 23 Our data are in agreement 
with earlier studies showing age-related increase of 
circulating adiponectin 82-86 and decrease of leptin 
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levels,87, 88 and with the well-recognized fact that both 
these adipokines are higher in women than in men. In 
previous reports, as in ours, PTH levels were signifi-
cantly associated with age and higher in women than 
in men.89-94 However, such influence of age and gen-
der on PTH was not observed in a recent study of 
35-65 year old healthy adults.95 These discrepancies 
might be due, at least partially, to the higher mean age 
in our cohort. 
Liver markers and comorbidities 
The high burden of pre-existing comorbidities at 
time of HF and its important affect on outcomes are 
well known, but the role and impact of liver function 
status on comorbidities has not yet been examined in 
the setting of HF. In our study, higher GGT levels 
(>30U/L), as might be expected, were associated with 
CAD, DM, and excess alcohol consumption, while 
lower ALT levels (≤20U/L) were associated with de-
mentia; total bilirubin levels above 20µmol/L were 
associated with CAD, cervical (vs. trochanteric) HF 
type and alcohol overuse, and albumin concentrations 
above 33g/L were associated with CAD. These find-
ings may indicate that even in the absence of overt 
liver disease hepatic functions are implicated in the 
pathogenesis of age-related disorders rather than 
merely be bystanders of ageing.  
Our findings are consistent with numerous 
studies and meta-analysis showing the association 
between serum GGT levels (within normal limits) and 
CAD,21-23, 46, 47, 77, 96-102 DM,25, 47, 103, 104 alcohol consump-
tion,32, 47, 105 cardiovascular and all-cause mortality in 
older adults,14, 18, 24, 105, 106 and the contribution of GGT 
to the pathogenesis of atherosclerotic plaques.46, 107, 108 
Our data are also consistent with reports that ALT is 
poorly linked to CVD,35, 36 and GGT (but not ALT), 
which is regarded as less specific for liver injury than 
ALT, is significantly associated with insulin resistance 
in non-diabetic subjects.109 Of note, results of our 
multivariate analysis demonstrated that DM and al-
cohol overuse were significant determinants of higher 
GGT (both as a continuous or categorical variable), 
but presence of CVD was not an independent pre-
dictor of GGT, suggesting that shared factors influ-
ence the pathogenetic relationship between the liver 
and CVD. The association of lower ALT levels with 
dementia is plausible given that ageing is a multidi-
mensional process and age-related decrease in ALT, a 
highly specific liver enzyme restricted to the cytosolic 
component of hepatocytes,110 may signify a decrease 
in the mass and function of the normal liver6, 7 in par-
allel with progressive decline of other vital functions.  
In our cohort, contrary to some previous studies, 
higher bilirubin levels were associated with CAD. 
Low bilirubin levels have been reported to be associ-
ated with CAD,111 its severity,112 increased carotid 
intima-media thickness,113 carotid atherosclerosis,114 
peripheral arterial disease,115 and total mortality,116 
while higher levels or mild to moderate elevations 
were associated with a protective effect against coro-
nary microvascular dysfunction,117 reduced cardio-
vascular events118 and stroke,119-121 as well as CAD in 
subjects with Gilbert syndrome.122 On the other hand, 
total bilirubin has been shown to be a strong and in-
dependent predictor of morbidity and mortality in 
patients with heart failure,123-126 acute myocardial in-
farction,127, 128 and after heart valve surgery.129  
Reports on the relationship between serum al-
bumin level and atherosclerotic CVD are also con-
flicting, demonstrating a negative,111, 130 positive,131-133 
or no association.134, 135 A recent study showed that 
higher albumin levels were associated with insulin 
resistance, but did not predict the development of 
diabetes.136 In our cohort, the odds ratio for presence 
of CAD was 3.1 in patients with serum albumin above 
33g/L. A possible explanation for the associations 
between higher bilirubin levels and/or normal albu-
minaemia with CVD is that individuals with lower 
bilirubin or albumin levels have already died by the 
time of HF. In the current as many previous 
studies61-68, 137 hypoalbuminaemia was strongly asso-
ciated with mortality. Therefore, the high-normal bil-
irubin and/or albumin levels in our older HF patients 
with CAD are not contradictory to observations of 
negative correlations between serum albumin and/or 
bilirubin levels and cardiovascular risk factors, as well 
as CAD.  
The abovementioned conflicting findings re-
garding the associations between liver markers and 
comorbidities might be attributable to different char-
acteristics of the study populations (age and sex dis-
tribution, alcohol consumption and smoking habits, 
obesity and insulin resistance, presence of metabolic 
syndrome or DM) and emphasise the complexity of 
the underlying mechanisms indicating the importance 
of an integrated approach to interpretation. 
Correlations: hepatic markers and adipokines, 
PTH and vitamin D 
To make matters even more difficult to the in-
terpretation of results, the literature data on the in-
ter-correlations between liver function markers, as 
well as on correlations between these markers and 
adipokines, and between adipokines and 25(OH) D 
and PTH in different pathologies are controversial.  
In our study, GGT activity and other hepatic 
markers exhibited a bidirectional relationship: a posi-
tive with ALT, ALP and bilirubin and a negative with 
albumin. These observations are in line with many, 
but not all,120 reports showing significant positive 
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correlations between GGT and ALT,5, 8, 138, 139 ALP140 
and bilirubin.141 These bidirectional links indicate that 
GGT activity represents an integral component of 
liver function.  
The adipocytokines adiponectin, leptin and re-
sistin, three best-studied pleiotropic hormones in-
volved in a number of physiological and pathophysi-
ological processes from energy homeostasis to in-
flammation and immunity, have been implicated in 
hepatic dysfunction.70, 142-150 However, in our cohort 
we were not able to demonstrate an association be-
tween leptin or resistin and liver markers, except 
higher mean resistin levels in patients with GGT>30 
U/L. 
In contrast, a main novelty of this study is a sig-
nificant positive correlation between serum adi-
ponectin, the most abundant adipocytokine, and GGT 
activity. Yet it should be noted that the robustness of 
adiponectin as an independent determinant of higher 
GGT become obvious after adjusting for important 
confounders (Table 5). Our results are in contrast with 
those observed in patients with type 2 DM,151, 152 vis-
ceral obesity,153 non-alcoholic hepatic steatosis 
(NASH),154, 155 as well as in healthy (often overweight 
and obese) individuals,96, 156-159 and Japanese male 
workers,160 in all of which adiponectin levels were 
negatively correlated with GGT. Although a signifi-
cant association between ALT and adiponectin was 
observed in young healthy men,161 in the majority of 
previous studies, as in ours, ALT and ALP levels were 
not associated with adiponectin.153, 155, 159, 162 Why ad-
iponectin is more strongly linked to GGT than to ALT 
and other liver markers is not entirely clear. Although 
serum GGT is predominantly secreted by the liver, it 
is present and active on the surface of most cell types 
where it plays an important role in glutathione me-
tabolism; GGT may also capture extra-hepatic pro-
cesses relevant to ageing. 
More importantly, while in DM, metabolic syn-
drome and NASH adiponectin levels are reduced and 
aminotransferase activities increased, in advanced 
liver disease, paradoxically, adiponectin levels are 
elevated and positively correlate with markers of liver 
cell injury, including GGT.163-165The contrasting find-
ings in the relationship between adiponectin and liver 
markers in these diseases may reflect different un-
derlying mechanisms. For example, the strong asso-
ciation between adiponectin and insulin resistance in 
the first group of conditions166, 167 was not observed in 
cirrhotic patients;164 in subjects with normal adi-
ponectin and leptin levels liver enzyme activities did 
not reflect insulin resistance.168 It has been suggested 
that the inverse association between adiponectin and 
insulin could be a function of suppressed adiponectin 
secretion by hyperinsulinemia,169 although in other 
studies higher adiponectin levels predicted lower 
incidence of diabetes independent of prevalent insulin 
resistance and glycemic status.170, 171 Possible expla-
nations for these conflicting associations should also 
include other factors influencing adiponectin levels, 
such as adipose mass, hepatic163 and renal172 catabo-
lism, natriuretic peptides, which directly stimulate 
adiponectin production,22 and adiponectin 
resistance.173 
The complex pathophysiological role of adi-
ponectin is further reflected in contradictory reports 
on the relationship between adiponectin levels and 
mortality in animal and human studies.174-181 
All these discrepancies should be interpreted in 
the context of known adiponectin “paradoxes”:182-185 
1) inverse association of circulating adiponectin level 
with body weight, obesity/visceral fat percentage; 2) 
metabolically beneficial effects of the hormone (an-
ti-atherogenic, anti-inflammatory, insulin sensitizing, 
anti-fibrinogenic and anti-apoptotic properties in the 
liver and other organs) well-documented in experi-
mental and human studies, low serum adiponectin 
concentrations in non-alcoholic fatty liver disease, 
atherosclerotic CVD (CAD, stroke, peripheral artery 
disease), hypertension, DM, metabolic syndrome, and 
cancers (prostate, colon, gastric, breast, leukemia) in 
contrast with increased adiponectin levels in ad-
vanced liver disease, including NASH-related cirrho-
sis, as well as in high-risk CVD patients, subjects with 
chronic heart failure, kidney, pulmonary and connec-
tive tissue diseases, preeclampsia, and in critically ill; 
3) its favorable (protective) associations with DM, 
metabolic syndrome and CVD in middle-aged cohorts 
and the opposite (increased risk of CVD, cardiovas-
cular outcomes and all-cause mortality) for older 
populations; 4) a U-shaped relationship with CVD, 
particularly CAD, and mortality in older adults ,186 
although the oldest-old individuals83, 187, 188 and cen-
tenarians173 have higher adiponectin levels than 
younger subjects. It appears, therefore, that in differ-
ent pathologies and age groups adiponectin may be 
regulated in opposite directions. 
In the present study, multivariate analysis 
showed that in older HF patients adiponectin is cor-
related positively with GGT in contrast to the inverse 
association reported in other cohorts, including 
healthy persons and, especially, patients with obesi-
ty-associated chronic diseases. The fact that adi-
ponectin was significantly higher in patients with 
GGT>30U/L, and GGT levels (after controlling for 
confounding factors) were bidirectionaly inversely 
correlated with albumin (synthetic liver function), 
and positively with other hepatic markers (ALT, ALP, 
bilirubin), but did not predict serum adiponectin 
concentration, indicates the important regulatory role 
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of adiponectin on serum GGT activity.  
The age-related increase in adiponectin and its 
positive association with GGT in our study were in-
dependent of other liver parameters (ALT, ALP, bili-
rubin and albumin), leptin (a sensitive marker of ad-
iposity negatively associated with adiponectin) and 
resistin (a biomarker strongly associated with an in-
flammatory response) levels, 25(OH)D, PTH, eGFR, 
alcohol consumption, presence of DM or CVD, alt-
hough some of these factors were also independent 
contributors to higher GGT levels (Table 4). In other 
words, the origin of higher serum GGT activity is 
multifactorial (eight factors accounted for 54.3% of 
GGT variance), and the elevated adiponectin concen-
tration and its relation to GGT are part of and reflect 
the complex homeostatic dysregulation(-s) that ac-
company ageing. Consistent with this hypothesis, are 
our findings demonstrating that PTH, which also in-
creases with age, correlated positively with adiponec-
tin and in the multivariate analysis was an inde-
pendent determinant of adiponectin (but not of leptin 
or resistin). Of note, despite the marked prevalence of 
vitamin D insufficiency in our cohort, with its associ-
ated increase in PTH, 25(OH)D levels were not inde-
pendent contributors of adiponectin, indicating a 
specific affect of higher PTH levels on production 
and/or release of adiponectin by adipocytes. Our re-
sults are in line with observations that 25(OH)D is not 
associated with adiponectin in nondiabetic obese 
adults,229 while PTH is independently associated with 
adiponectin in patients with heart failure.189 However, 
in patients with primary hyperparathyroidism adi-
ponectin concentrations were found to be normal190 or 
reduced,191, 192 did not changed or reversed by para-
thyroidectomy,190, 192 and were not associated with 
PTH levels.193 The complex multifactorial origin of 
GGT activity is further suggested by our observation 
of its significant correlation with TSH (positive) and 
T4 (negative); thyroid hormones are known to play an 
important role in oxidative stress balance.194  
The positive correlation between PTH and adi-
ponectin has not been previously documented in HF 
patients, and it may explain, at least partially, the ad-
iponectin-GGT “paradox”: although in general with 
ageing GGT activity decreases, adiponectin levels, 
mediated in part by elevated PTH, rise resulting in 
higher GGT levels. We hypothesise that PTH eleva-
tion may partly contribute to higher adiponectin 
concentration, which is clearly related to higher GGT.  
Towards an integrated and unifying hypothesis 
Our data in line with numerous previous publi-
cations showed that decline in liver functions, in-
crease in adiponectin and PTH are interconnected 
universal phenomena associated with human ageing. 
Age-related rise in serum adiponectin and PTH con-
centrations are positively correlated, but age and ad-
iponectin are paradoxically compatible with hepatic 
function, especially with GGT activity. In parallel 
with adiponectin elevation GGT activity increases 
indicating that the hormonal effect of adiponectin 
takes precedence over age-related suppression in the 
enzyme activity. The serum GGT activity reflects the 
integrated response of these opposite effects. 
These observations raised two key questions: 1) 
is there a special common cause that underlies the 
metabolic changes occurring with advancing age, 
although each change results from an interplay of 
numerous independent mechanisms, and 2) is higher 
serum adiponectin concentration associated with 
GGT elevation, as in our case, an adop-
tive/compensatory response or a harmful effect.  
The exact answers remain largely unknown, and 
any attempt to adequately explain the observations 
should include at least two fundamental mechanisms: 
homeostasis and oxidative stress. Several lines of ev-
idence suggest close but complex interactions be-
tween oxidative stress and GGT, albumin, bilirubin, 
adiponectin and PTH (these factors may act as causes 
and consequences of oxidative stress). Oxidative 
stress, an imbalance between the production and in-
activation of reactive oxygen species in favour of ox-
idants accumulation, is widely accepted as an im-
portant mechanism associated with human ageing 
and its adverse effects.195-199 Hepatic aging is associ-
ated with greater oxidative stress and cell 
apoptosis.200-202 GGT, a membrane-bound enzyme, 
plays a pivotal role in the intracellular antioxidant 
defence being involved in the gamma-glutamyl cycle 
by which extracellular glutathione is transported into 
cells. Depletion of intracellular glutathione, a princi-
pal intracellular antioxidant,203 in response to oxida-
tive stress results in an increase in GGT so that the 
metabolic homeostasis are maintained. Serum GGT 
activity is inversely associated with the concentration 
of serum antioxidants.204 Serum GGT within its nor-
mal range is recognized as a sensitive marker of oxi-
dative stress.30, 141, 203-207 However, in physiological 
conditions, GGT may also act as a pro-oxidant,203, 204, 
208 generating reactive oxygen species,209, 210 which 
could exceed the capacity of the antioxidant system 
and induce cellular oxidative stress damage. 
The oxidative stress responses involve also other 
potent antioxidants, namely albumin,211 the major 
protein in plasma, which accounts 80% of thiol’s an-
tioxidant effect in the body,212, 213 bilirubin, which 
protects cells from a 10 000-fold excess of oxidants 
through rapid regeneration of bilirubin by biliverdin 
reductase,119, 214 and adiponectin. In animal models215, 
216 and in humans,217, 218 including the elderly,219 adi-
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ponectin inhibits oxidative stress, but oxidative stress 
suppresses adiponectin production and its powerful 
protective antioxidant properties.220 Importantly, ad-
iponectin is also involved in apoptosis, an evolution-
ary conserved controlled-death program, which en-
sures proper regulation of the size and quality of cell 
populations in tissues.221 PTH may affect oxidative 
stress directly or by intracellular calcium accumula-
tion.222, 223 In other words, GGT, albumin, bilirubin, 
adiponectin and PTH, all of which play a critical role 
in homeostasis, may be elicited by oxidative stress 
and/or may have both protective and promoting ef-
fects on oxidative stress. The interplay and high de-
gree of complexity of aforementioned and other fac-
tors involved in oxidative stress indicate the role of 
regulatory feedback mechanisms in different condi-
tions. Normally, the oxidative stress responses main-
tain metabolic homeostasis and are beneficial for ad-
aptation and survival, while dysregulation in the 
feedback processes may cause the vicious cycle(-s) of 
oxidants overproduction resulting in aging and ag-
ing-related diseases.224 Despite considerable gaps in 
our knowledge, emerging data suggests that adi-
ponectin and oxidative stress can function in both a 
defence and harmful manner. 
In regard to our observations, age-related de-
crease of GGT activity may reflect the decline not only 
in liver function, but in the whole antioxidant defence 
system (including the decrease in the antioxidant ef-
fects of albumin as one of its components), and the 
increase in serum GGT level may be a compensatory 
response to oxidative stress, a recognised hallmark of 
ageing and chronic diseases. This response includes 
increases in PTH and adiponectin. The former is at 
least in part responsible for the adiponectin elevation, 
while the later enhances the anti-oxidant potential in 
the cells by increasing GGT and promotes 
apoptosis.225 In this way, it can be hypothesized that 
in our patients, higher GGT activity which is posi-
tively associated with both adiponectin and bilirubin 
(also a potent antioxidant) levels, reflects a compen-
satory response to oxidative stress. However, in the 
setting of advanced age and co-morbidities this re-
sponse is unable fully counter-regulate the oxidative 
damage and prevent its progression if oxidative stress 
increases, as in the perioperative period. Indeed, in 
our cohort, both GGT and adiponectin above the me-
dian levels were independently and synergistically 
associated with prolonged LOS, but not with 
in-hospital mortality, whereas even mild decrease in 
albumin concentration, an important extracellular 
antioxidant, demonstrated a strong relation to fatal 
outcome. These complex interactions are summarised 
in Figure 3.  
 
 
Figure 3. Diagram illustrating complex interplay between ageing, oxida-
tive stress, parathyroid hormone (PTH), adiponectin and gam-
ma-glutamyltransferase (GGT) and other hepatic markers and their 
relation to short-term outcomes in older patients with hip fracture. LOS, 
length of hospital stay. In advanced age, GGT, albumin, bilirubin, adiponectin and PTH, 
all of which are influenced by oxidative stress, may exert both protective and pro-
moting effects on oxidant formation, affect each other, and contribute to poor 
outcomes. Excessive PTH along with different other age-related factors drives 
adiponectin levels higher, and such elevations increase GGT activity which reflects an 
integrative adaptive/compensatory or pathological response (homeostatic regulation 
or dysregulation). In HF patients, both GGT and adiponectin concentrations above 
the median levels are independent markers of prolonged LOS and contribute syn-
ergistically to this outcome, hypoalbuminaemia is associated with in-hospital death, 
and hyperparathyroidism is an independent predictor of both fatal outcome and 
prolonged hospital stay. 
 
Liver markers and short-term outcomes 
Our data shows that in older HF patients liver 
markers (usually within the normal ranges) on ad-
mission are associated with a continuum of risk for 
poor outcomes. Of clinical interest, GGT, albumin and 
adiponectin levels analysed as categorical variables 
(given the practical convenience of cut-off values), 
independently of known risk factors, may help to 
identify subjects at increased risk of prolonged hos-
pital stay (LOS>20 days) and in-hospital death. Pa-
tients with GGT>30U/L and albumin<33g/L were 
near two times as likely to have a LOS>20 days, and 
more than 3 times as likely to have died during hos-
pitalisation, respectively, compared to those without 
such conditions. The calculated sensitivity and speci-
ficity of serum GGT>30U/L for discriminating those 
with LOS>20 days were 48.9% and 65.8%, respec-
tively, and of albumin <33g/L for prediction 
in-hospital death were 42.9% and 78.9%, respectively; 
serum albumin<33g/L on admission had a NPV of 
96.5%. The risk of LOS>20 days also doubled in sub-
jects with adiponectin>17.14 ng/L (median level). 
Furthermore, joint effects of GGT>30U/L and adi-
ponectin>17.14 ng/ml raised the odds of LOS>20 
days by 4.7–fold, demonstrating synergism; the spec-
ificity of two markers in combination for predicting 
LOS>20 days was 83.2%. These two biomarkers, alt-
hough interrelated, are associated with different 
pathogenetic processes, and, not surprisingly, when 
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measured in parallel are more informative for pre-
dicting LOS.  
Our observations are in line with previous re-
ports that low albumin is of prognostic value on 
mortality in HF patients.61, 62, 65, 66, 69, 137, 226-228 Our data 
are also concordant with clinical observations that 
demonstrate that serum GGT, a robust predictor of 
mortality due to CVD in younger individuals, did not 
predict mortality in individuals aged 70 years or 
more.69 The prognostic value of GGT and/or adi-
ponectin in HF patients has not been reported previ-
ously. Of note, in contrast to the present multivariate 
analyses, most of the previous prognostic studies in 
patients with HF examined only few liver parameters 
(mainly albumin) and often did not control for possi-
ble confounders, clinical and laboratory.67  
The reason(-s) for prolonged LOS among pa-
tients with higher GGT and/or higher adiponectin 
remains unclear. The finding that only GGT and not 
ALT (a more specific marker of hepatic function), 
ALP, bilirubin or albumin was associated with LOS in 
adjusted models may suggest that the GGT -- LOS 
association reflects not only the liver status but the 
increased oxidative stress. 
The additional (albeit moderate) prognostic in-
formation to HF outcomes provided by liver markers, 
accurate and not expensive laboratory tests, could be 
helpful in early identification and appropriate treat-
ment of this frail population, and, consequently, im-
prove outcomes, especially prolonged LOS. Current-
ly, HFs represent about two-thirds of all hospital days 
due to fracture and account for more hospital days 
than any other musculoskeletal injury.228 
Limitations and strength of the study 
Several limitations of this study should be con-
sidered. First, it was a cross-sectional analysis and, 
therefore, the cause-effect relationship could not be 
determined. Second, we measured serum GGT activ-
ity and total adiponectin, but the GGT fractions and 
high-molecular weight adiponectin¸ shown in some, 
but not all,185 studies to be more informative, were not 
assessed. Third, potential effects of confounding from 
variables not represented in our models (e.g. medica-
tion used) cannot be excluded. Forth, as the cohort 
was mainly Caucasian our findings may not be gen-
eralizible to other ethnic groups. 
The strengths of this study are its prospective 
design, and the amount of obtained variables. Alt-
hough multiple comparisons may potentiate the sig-
nificance of multicollinearity phenomena in multi-
variate regression analysis, the variance inflation fac-
tor in all models presented in Tables 4 and 5 was less 
than 1.3, indicating that the amount of multicollinear-
ity was not significant.  
Conclusions 
The present study of older persons with hip 
fracture demonstrates that biochemical parameters of 
liver function even within its normal range in the 
majority of patients are relevant to comorbidities and 
outcomes, documents the regulatory role of adi-
ponecin (but not leptin or resistin) as an independent 
contributor to GGT activity, and shows that serum 
GGT (>30 IU/L) and albumin (<33g/L) levels on ad-
mission may be helpful in predicting prolonged hos-
pital stay and in-hospital death, respectively. 
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